Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Copley Pharmaceuticals

  • News

Executive Summary

Generic drug firm expects to commence 1.9 mil. share initial public offering in mid-October. In an amended registration statement filed Sept. 14, Copley raised the estimated price-per-share from $14-$16 to $17-$19. The preliminary prospectus was filed April 24 ("The Pink Sheet" May 25, p. 7). Proceeds are estimated at $30.8 mil., based on $18 per share price. Copley has received 12 ANDA approvals in 1992, and a total of 38 ANDAs to date. The firm has had a total of 11 first ANDAs, of which seven are still the exclusive generic product approval. Copley holds the second tentative ANDA approval for Marion Merrell Dow's Cardizem (diltiazem), not Lederle ("The Pink Sheet" Sept. 7, T&G-2). Lederle's tentative approval was third chronologically.

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS021482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By